尿路感染症市場：適応症別、治療法別、エンドユーザー別-2025-2030年の世界予測

尿路感染症市場は、2023年に116億7,000万米ドルと評価され、2024年には124億7,000万米ドルに達すると予測され、CAGR 6.93％で成長し、2030年には186億7,000万米ドルに達すると予測されています。

尿路感染症（尿路結石）市場には、泌尿器系に影響を及ぼす感染症の予防と管理に関連する診断薬、治療薬、機器が含まれます。尿路結石への対処の必要性は、特に女性におけるその高い有病率に起因しており、頻繁な再発は重大なヘルスケア上の課題となっています。治療は、初期診断サービスを提供するプライマリ・ケアから、高度な治療ソリューションを提供する専門病院まで多岐にわたる。最終用途分野には、個人患者、ヘルスケア施設、診断研究所が含まれます。この市場に影響を与える主な成長要因は、世界の尿路結石の負担増、診断技術の発展、ヘルスケア意識の高まり、標的抗生物質や免疫療法ソリューションの開発などです。市場は、迅速なポイントオブケア検査キットや個別化医療アプローチなど、最先端の製品開拓によるビジネスチャンスを目の当たりにしています。企業は、研究開発に投資して迅速診断技術や非抗生物質療法の選択肢を革新することで、こうした機会を活用することができ、精密医療に向けた傾向の高まりに対応することができます。

しかし、市場は抗生物質耐性による限界に直面しています。耐性は既存の治療法の有効性に課題をもたらし、費用と時間のかかる新薬開拓の必要性を促しています。さらに、革新的な治療法に対する厳しい規制の枠組みが、新しい解決策の市場参入を遅らせる可能性もあります。こうした障壁を克服するためには、抗生物質の技術革新を加速させるための製薬会社とバイオテクノロジー企業の協力や、自然療法や代替療法の道を探ることが実行可能な解決策となり得る。特に、耐性菌のいない抗生物質の市場開拓、予防的ソリューションとしてのプロバイオティクスの探求、患者の状態を遠隔でモニタリング・管理するためのデジタル・ヘルスケア・アプリケーションなど、この市場には技術革新の余地が大きいです。市場が進化する中、企業は消費者の行動や規制状況の変化に適応し、持続的な成長とダイナミックなヘルスケア環境における競合優位性を維持するために、機敏な対応を優先する必要があります。

市場力学：急速に進化する尿路感染症市場の主要な市場インサイトを公開

尿路感染症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 糖尿病および腎臓結石の有病率の増加
  • 女性人口における尿路結石の高い発生率
  • 抗生物質の過剰使用と薬剤耐性の増加による複雑な尿路結石症
• 市場抑制要因
  • アミノグリコシド系やアゾール系などの尿路感染症治療薬の副作用
• 市場機会
  • 新規クラスの抗生物質、ワクチン、デバイスの研究開発の増加
  • 人々の意識とヘルスケア支出の増加
• 市場の課題
  • 尿路感染症に関する社会的偏見

ポーターのファイブフォース：尿路感染症市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：尿路感染症市場における外部からの影響の把握

外部マクロ環境要因は、尿路感染症市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析尿路感染症市場における競合情勢の把握

尿路感染症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス尿路感染症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、尿路感染症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病と腎臓結石の罹患率の増加
    • 女性人口における尿路感染症の発生率が高い
    • 抗生物質の過剰使用と薬剤耐性の増加による複雑な尿路感染症
  • 抑制要因
    • アミノグリコシドやアゾールなどの治療薬の副作用
  • 機会
    • 新しい種類の抗生物質、ワクチン、デバイスの研究開発の増加
    • 国民の意識とヘルスケア費の増加
  • 課題
    • 尿路感染症に関する社会的偏見
• 市場セグメンテーション分析
  • 臨床適応症：腎盂腎炎の管理のための強力かつ高度な薬物療法戦略の必要性
  • エンドユーザー：遠隔医療や電子医療プラットフォームの普及による自己管理ソリューションの改善に向けた最近の進歩
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 尿路感染症市場臨床適応症別

• 膀胱炎
• 腎盂腎炎
• 尿道炎

第7章 尿路感染症市場治療別

• 診断
• 治療薬
  • アミノグリコシド
  • アゾール
  • キノロン
  • β-ラクタム

第8章 尿路感染症市場：エンドユーザー別

• 病院
• 自己管理

第9章 南北アメリカの尿路感染症市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の尿路感染症市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの尿路感染症市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Vivoo、CESで自宅で使えるデジタルUTI検査を発表2024
  • NRx Pharmaceuticals社、複雑性尿路感染症の治療薬NRX-101の治験薬（IND）申請がFDAに承認されたと発表
  • イントロン、尿路感染症用バクテリオファージで米国軍と協力

企業一覧

• Dr. Reddys Laboratories Ltd.
• Sysmex Corporation
• AstraZeneca PLC
• URIT Medical Electronic Co., Ltd.
• Novartis AG
• Cipla Limited
• Pfizer Inc.
• Bayer AG
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Boehringer Ingelheim International GmbH
• Shionogi & Co., Ltd.
• Siemens Healthcare AG
• AbbVie Inc.
• F. Hoffmann-La Roche AG
• Sun Pharmaceutical Industries Limited
• Bristol-Myers Squibb Company
• GlaxoSmithKline PLC
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Almirall, S.A.
• Eli Lilly and Company
• Viatris Inc.
• Merck & Co. Inc.
• Novo Nordisk A/S

LIST OF FIGURES

• FIGURE 1. URINARY TRACT INFECTION MARKET RESEARCH PROCESS
• FIGURE 2. URINARY TRACT INFECTION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. URINARY TRACT INFECTION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. URINARY TRACT INFECTION MARKET DYNAMICS
• TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 37. CANADA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 38. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 59. CHINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 60. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 63. INDIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 64. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 132. ITALY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 133. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. POLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 148. POLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 149. POLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 152. QATAR URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 153. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

The Urinary Tract Infection Market was valued at USD 11.67 billion in 2023, expected to reach USD 12.47 billion in 2024, and is projected to grow at a CAGR of 6.93%, to USD 18.67 billion by 2030.

The urinary tract infection (UTI) market encompasses diagnostics, therapeutic treatments, and devices related to the prevention and management of infections affecting the urinary system. The necessity of addressing UTIs arises due to their high prevalence, particularly among women, with frequent recurrences posing a significant healthcare challenge. Applications extend from primary care settings offering initial diagnostic services to specialized hospitals providing advanced treatment solutions. End-use sectors include individual patients, healthcare facilities, and diagnostic laboratories. Key growth factors influencing this market are the increasing burden of UTIs globally, advancements in diagnostic technologies, a rise in healthcare awareness, and the development of targeted antibiotics and immunotherapy solutions. The market is witnessing opportunities from cutting-edge product developments such as rapid point-of-care testing kits and personalized medicine approaches. Companies can capitalize on these opportunities by investing in R&D to innovate rapid diagnostic technologies and non-antibiotic therapeutic options, aligning with the growing trend towards precision healthcare.

However, the market faces limitations due to antibiotic resistance, which challenges the effectiveness of existing treatments and drives the need for new drug development, which can be expensive and time-consuming. Furthermore, stringent regulatory frameworks for innovative therapies may delay market entry of novel solutions. To overcome these barriers, collaboration between pharmaceutical companies and biotech firms for accelerated antibiotic innovation and exploring natural and alternative medicine avenues can be viable solutions. The market presents significant areas for innovation, particularly in the development of resistance-free antibiotics, exploration of probiotics as preventive solutions, and digital healthcare applications for monitoring and managing patient conditions remotely. As the market is evolving, firms need to prioritize agile practices to adapt to shifting consumer behaviors and regulatory landscapes, ensuring sustained growth and maintaining competitive advantage in a dynamic healthcare environment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Urinary Tract Infection Market

The Urinary Tract Infection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Prevalence of Diabetes and Kidney Stones
  • High Incidences of UTI in Female Population
  • Complicated UTI due to Rise in Excessive Use of Antibiotics and Drug-Resistance
• Market Restraints
  • Adverse Effects of Urinary Tract Infection Treatment Drugs such as Aminoglycosides and Azoles
• Market Opportunities
  • Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
  • Increase in Awareness among People and Healthcare Expenditure
• Market Challenges
  • Social Stigma Concerning Urinary Tract Infections

Porter's Five Forces: A Strategic Tool for Navigating the Urinary Tract Infection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Urinary Tract Infection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Urinary Tract Infection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Urinary Tract Infection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Urinary Tract Infection Market

A detailed market share analysis in the Urinary Tract Infection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Urinary Tract Infection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Urinary Tract Infection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Urinary Tract Infection Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddys Laboratories Ltd., Sysmex Corporation, AstraZeneca PLC, URIT Medical Electronic Co., Ltd., Novartis AG, Cipla Limited, Pfizer Inc., Bayer AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Boehringer Ingelheim International GmbH, Shionogi & Co., Ltd., Siemens Healthcare AG, AbbVie Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Limited, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Almirall, S.A., Eli Lilly and Company, Viatris Inc., Merck & Co. Inc., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the Urinary Tract Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Clinical Indication, market is studied across Cystitis, Pyelonephritis, and Urethritis.
• Based on Treatment, market is studied across Diagnosis and Therapatics. The Therapatics is further studied across Aminoglycosides, Azoles, Quinolones, and B-lactam.
• Based on End User, market is studied across Hospitals and Self-Administered.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Prevalence of Diabetes and Kidney Stones
    • 5.1.1.2. High Incidences of UTI in Female Population
    • 5.1.1.3. Complicated UTI due to Rise in Excessive Use of Antibiotics and Drug-Resistance
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse Effects of Urinary Tract Infection Treatment Drugs such as Aminoglycosides and Azoles
  • 5.1.3. Opportunities
    • 5.1.3.1. Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
    • 5.1.3.2. Increase in Awareness among People and Healthcare Expenditure
  • 5.1.4. Challenges
    • 5.1.4.1. Social Stigma Concerning Urinary Tract Infections
• 5.2. Market Segmentation Analysis
  • 5.2.1. Clinical Indication: Need for potent and advanced medication strategies for the management of pyelonephritis
  • 5.2.2. End User: Recent advancements to improve self-administration solutions through the proliferation of telemedicine and e-health platforms
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Urinary Tract Infection Market, by Clinical Indication

• 6.1. Introduction
• 6.2. Cystitis
• 6.3. Pyelonephritis
• 6.4. Urethritis

7. Urinary Tract Infection Market, by Treatment

• 7.1. Introduction
• 7.2. Diagnosis
• 7.3. Therapatics
  • 7.3.1. Aminoglycosides
  • 7.3.2. Azoles
  • 7.3.3. Quinolones
  • 7.3.4. B-lactam

8. Urinary Tract Infection Market, by End User

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Self-Administered

9. Americas Urinary Tract Infection Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Urinary Tract Infection Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Urinary Tract Infection Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Vivoo launches at-home digital UTI test at CES 2024
  • 12.3.2. NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
  • 12.3.3. Intron enters collaboration with the US Army on bacteriophages for urinary tract infections

Companies Mentioned

• 1. Dr. Reddys Laboratories Ltd.
• 2. Sysmex Corporation
• 3. AstraZeneca PLC
• 4. URIT Medical Electronic Co., Ltd.
• 5. Novartis AG
• 6. Cipla Limited
• 7. Pfizer Inc.
• 8. Bayer AG
• 9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 10. Boehringer Ingelheim International GmbH
• 11. Shionogi & Co., Ltd.
• 12. Siemens Healthcare AG
• 13. AbbVie Inc.
• 14. F. Hoffmann-La Roche AG
• 15. Sun Pharmaceutical Industries Limited
• 16. Bristol-Myers Squibb Company
• 17. GlaxoSmithKline PLC
• 18. Teva Pharmaceutical Industries Ltd.
• 19. Johnson & Johnson Services, Inc.
• 20. Almirall, S.A.
• 21. Eli Lilly and Company
• 22. Viatris Inc.
• 23. Merck & Co. Inc.
• 24. Novo Nordisk A/S